Artal Group S.A. - SYROS PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
Artal Group S.A. ownership history of SYROS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$5,829
+25.4%
1,475,7440.0%0.25%
+73.6%
Q2 2023$4,649
+18.0%
1,475,7440.0%0.14%
-38.5%
Q1 2023$3,940
-25.0%
1,475,744
+0.8%
0.23%
-20.1%
Q4 2022$5,255
-99.9%
1,463,8290.0%0.29%
-27.1%
Q3 2022$9,427,0001,463,8290.40%
Other shareholders
SYROS PHARMACEUTICALS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 868,403$3,117,5673.03%
Bain Capital Life Sciences Investors, LLC 2,124,694$7,6280.85%
Samsara BioCapital, LLC 881,450$3,164,4060.68%
Altium Capital Management LP 315,070$1,131,1010.58%
Omega Fund Management, LLC 251,270$902,0590.30%
Artal Group S.A. 1,463,829$5,2550.29%
DAFNA Capital Management LLC 265,878$954,5020.27%
CVI Holdings, LLC 425,500$1,527,5450.20%
Flagship Pioneering Inc. 993,848$3,567,9140.11%
Avidity Partners Management LP 900,000$3,231,0000.07%
View complete list of SYROS PHARMACEUTICALS INC shareholders